Immunization with fibrillar Aβ1-42 in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Aβ

Elizabeth Head; Edward G. Barrett; M. Paul Murphy; Pritam Das; Mihaela Nistor; Floyd Sarsoza; Charles C. Glabe; Rakez Kayed; Saskia Milton; Vitaly Vasilevko; Norton W. Milgram; Michael G. Agadjanyan; David H. Cribbs; Carl W. Cotman

doi:10.1016/j.vaccine.2005.12.058

Immunization with fibrillar Aβ_1-42 in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Aβ

Elizabeth Head
, Edward G. Barrett
, M. Paul Murphy
, Pritam Das
, Mihaela Nistor
, Floyd Sarsoza
, Charles C. Glabe
, Rakez Kayed
, Saskia Milton
, Vitaly Vasilevko
, Norton W. Milgram
, Michael G. Agadjanyan
, David H. Cribbs
, Carl W. Cotman

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

We describe a study testing fibrillar β-amyloid_1-42 (Aβ₄₂) vaccination in dogs. Three young beagles (4.6 years) were immunized twice with Aβ₄₂ and a Th1 adjuvant (TiterMax Gold). Animals generated primarily IgG₂ and IgM antibody responses, which were specific for the Aβ_11-30 region of Aβ_1-42. Next, 3 aged beagles (8.9-13.8 years) were immunized 4 times with Aβ₄₂ and a Th2 adjuvant (Alum). We observed an acute increase in IgG_2, a slower increase in IgG₁ and Aβ antibodies of broader specificity (Aβ_1-15> Aβ_11-30> Aβ_6-20). A nonsignificant increase in CSF Aβ_1-40 and decrease in Aβ_1-40/1-42 in cortex was detected. Canines may be a useful system for testing an Aβ vaccine.

Original language	English
Pages (from-to)	2824-2834
Number of pages	11
Journal	Vaccine
Volume	24
Issue number	15
DOIs	https://doi.org/10.1016/j.vaccine.2005.12.058
State	Published - Apr 5 2006

Funding

Funders	Funder number
National Institute on Aging	R01AG020241

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Alum
Alzheimer's disease
Beta-amyloid
Brain aging
Dog

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2005.12.058

Cite this

Head, E., Barrett, E. G., Murphy, M. P., Das, P., Nistor, M., Sarsoza, F., Glabe, C. C., Kayed, R., Milton, S., Vasilevko, V., Milgram, N. W., Agadjanyan, M. G., Cribbs, D. H., & Cotman, C. W. (2006). Immunization with fibrillar Aβ_1-42 in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Aβ. Vaccine, 24(15), 2824-2834. https://doi.org/10.1016/j.vaccine.2005.12.058

@article{e61fb0e8326e4d68a454a292381c4bfc,

title = "Immunization with fibrillar Aβ1-42 in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Aβ",

abstract = "We describe a study testing fibrillar β-amyloid1-42 (Aβ42) vaccination in dogs. Three young beagles (4.6 years) were immunized twice with Aβ42 and a Th1 adjuvant (TiterMax Gold). Animals generated primarily IgG2 and IgM antibody responses, which were specific for the Aβ11-30 region of Aβ1-42. Next, 3 aged beagles (8.9-13.8 years) were immunized 4 times with Aβ42 and a Th2 adjuvant (Alum). We observed an acute increase in IgG2, a slower increase in IgG1 and Aβ antibodies of broader specificity (Aβ1-15> Aβ11-30> Aβ6-20). A nonsignificant increase in CSF Aβ1-40 and decrease in Aβ1-40/1-42 in cortex was detected. Canines may be a useful system for testing an Aβ vaccine.",

keywords = "Alum, Alzheimer's disease, Beta-amyloid, Brain aging, Dog",

author = "Elizabeth Head and Barrett, \{Edward G.\} and Murphy, \{M. Paul\} and Pritam Das and Mihaela Nistor and Floyd Sarsoza and Glabe, \{Charles C.\} and Rakez Kayed and Saskia Milton and Vitaly Vasilevko and Milgram, \{Norton W.\} and Agadjanyan, \{Michael G.\} and Cribbs, \{David H.\} and Cotman, \{Carl W.\}",

year = "2006",

month = apr,

day = "5",

doi = "10.1016/j.vaccine.2005.12.058",

language = "English",

volume = "24",

pages = "2824--2834",

number = "15",

}

Head, E, Barrett, EG, Murphy, MP, Das, P, Nistor, M, Sarsoza, F, Glabe, CC, Kayed, R, Milton, S, Vasilevko, V, Milgram, NW, Agadjanyan, MG, Cribbs, DH & Cotman, CW 2006, 'Immunization with fibrillar Aβ_1-42 in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Aβ', Vaccine, vol. 24, no. 15, pp. 2824-2834. https://doi.org/10.1016/j.vaccine.2005.12.058

TY - JOUR

T1 - Immunization with fibrillar Aβ1-42 in young and aged canines

T2 - Antibody generation and characteristics, and effects on CSF and brain Aβ

AU - Head, Elizabeth

AU - Barrett, Edward G.

AU - Murphy, M. Paul

AU - Das, Pritam

AU - Nistor, Mihaela

AU - Sarsoza, Floyd

AU - Glabe, Charles C.

AU - Kayed, Rakez

AU - Milton, Saskia

AU - Vasilevko, Vitaly

AU - Milgram, Norton W.

AU - Agadjanyan, Michael G.

AU - Cribbs, David H.

AU - Cotman, Carl W.

PY - 2006/4/5

Y1 - 2006/4/5

N2 - We describe a study testing fibrillar β-amyloid1-42 (Aβ42) vaccination in dogs. Three young beagles (4.6 years) were immunized twice with Aβ42 and a Th1 adjuvant (TiterMax Gold). Animals generated primarily IgG2 and IgM antibody responses, which were specific for the Aβ11-30 region of Aβ1-42. Next, 3 aged beagles (8.9-13.8 years) were immunized 4 times with Aβ42 and a Th2 adjuvant (Alum). We observed an acute increase in IgG2, a slower increase in IgG1 and Aβ antibodies of broader specificity (Aβ1-15> Aβ11-30> Aβ6-20). A nonsignificant increase in CSF Aβ1-40 and decrease in Aβ1-40/1-42 in cortex was detected. Canines may be a useful system for testing an Aβ vaccine.

AB - We describe a study testing fibrillar β-amyloid1-42 (Aβ42) vaccination in dogs. Three young beagles (4.6 years) were immunized twice with Aβ42 and a Th1 adjuvant (TiterMax Gold). Animals generated primarily IgG2 and IgM antibody responses, which were specific for the Aβ11-30 region of Aβ1-42. Next, 3 aged beagles (8.9-13.8 years) were immunized 4 times with Aβ42 and a Th2 adjuvant (Alum). We observed an acute increase in IgG2, a slower increase in IgG1 and Aβ antibodies of broader specificity (Aβ1-15> Aβ11-30> Aβ6-20). A nonsignificant increase in CSF Aβ1-40 and decrease in Aβ1-40/1-42 in cortex was detected. Canines may be a useful system for testing an Aβ vaccine.

KW - Alum

KW - Alzheimer's disease

KW - Beta-amyloid

KW - Brain aging

KW - Dog

UR - https://www.scopus.com/pages/publications/33644920371

UR - https://www.scopus.com/pages/publications/33644920371#tab=citedBy

U2 - 10.1016/j.vaccine.2005.12.058

DO - 10.1016/j.vaccine.2005.12.058

M3 - Article

C2 - 16460841

AN - SCOPUS:33644920371

SN - 0264-410X

VL - 24

SP - 2824

EP - 2834

JO - Vaccine

JF - Vaccine

IS - 15

ER -